Author + information
- Received November 6, 2017
- Revision received December 18, 2017
- Accepted January 2, 2018
- Published online March 5, 2018.
- Edward L. Hannan, PhDa,∗ (, )
- Zaza Samadashvili, MDa,
- Kimberly Cozzens, MAa,
- Peter B. Berger, MDb,
- Joanna Chikwe, MDc,
- Alice K. Jacobs, MDd,
- Gary Walford, MDe,
- Frederick S.K. Ling, MDf,
- Ferdinand J. Venditti, MDg,
- Jeffrey Gold, MDh and
- Spencer B. King III, MDi
- aCardiac Services Program, University at Albany, State University of New York, Albany, New York
- bNYS Cardiac Advisory Committee, Albany, New York
- cDepartment of Cardiothoracic Surgery, Stony Brook School of Medicine, Stony Brook, New York
- dDepartment of Cardiology, Boston Medical Center, Boston, Massachusetts
- eDepartment of Medicine (Cardiology), Johns Hopkins University, Baltimore, Maryland
- fDepartment of Medicine (Cardiology), University of Rochester Medical Center, Rochester, New York
- gSystem Care Delivery, Albany Medical Center, Albany, New York
- hUniversity of Nebraska Medical Center, Omaha, Nebraska
- iDepartment of Medicine, St. Joseph’s Health System, Atlanta, Georgia
- ↵∗Address for correspondence:
Dr. Edward L. Hannan, State University of New York, University at Albany, One University Place, Rensselaer, New York 12144-3456.
Objectives The purpose of this study is to revisit cases rated as “inappropriate” in the 2012 appropriate use criteria (AUC) using the 2017 AUC.
Background AUC for coronary revascularization in patients with stable ischemic heart disease (SIHD) were released in January 2017. Earlier 2012 AUC identified a relatively high percentage of New York State patients for whom percutaneous coronary intervention (PCI) was rated as “inappropriate” versus optimal medical therapy alone.
Methods New York State’s PCI registry was used to rate inappropriateness of patients undergoing PCI in 2014 using the 2012 and 2017 AUC, and to examine patient characteristics for patients rated differently.
Results A total of 911 of 9,261 (9.8%) patients who underwent PCI in New York State in 2014 with SIHD without prior coronary artery bypass grafting were rated as “inappropriate” using the 2012 AUC, but only 171 (1.8%) patients were rated as “rarely appropriate” (“inappropriate” in 2012 AUC terminology) using the 2017 AUC. A total of 26% of all 8,407 patients undergoing PCI in New York State with 1- to 2-vessel SIHD were without high-risk findings on noninvasive testing and were either asymptomatic or without antianginal therapy. No current or past randomized controlled trials have focused on these patients.
Conclusions The percentage of 2014 New York State PCI patients with SIHD who are rated “rarely appropriate” has decreased substantially using 2017 AUC in comparison with the older 2012 AUC. However, for many low-risk patients undergoing the procedure, the relative benefits of optimal medical therapy with and without PCI are unknown. Randomized controlled trials are needed to study these groups.
- coronary revascularization appropriateness
- percutaneous coronary intervention
- stable ischemic heart disease
Dr. Berger has served on the executive steering committee for trials funded by Janssen and Medicure. Dr. Jacobs has served as a site principal investigator for Abbott Vascular and AstraZeneca. Dr. King has served on the Data Safety Monitoring Board for the Harvard Clinical Research Institute, Duke University, Capicor Inc., Merck & Company, and Stentys. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received November 6, 2017.
- Revision received December 18, 2017.
- Accepted January 2, 2018.
- 2018 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.